Peptide News Digest

MindRank $52M Series B for AI-Designed Oral GLP-1 MDR-001 in Phase 3 MOBILE Trial in China, White House Reviewing Three FDA Commissioner Finalists Heidi Overton, Jeffrey Vacirca, and Stephen Ferrara, Washington Post Health Brief 'The Peptide Showdown' Sustains Mainstream Coverage Two Weeks Before PCAC Vote, AstraZeneca and Ionis Wainua (Eplontersen) CARDIO-TTRansform Phase 3 Miss in ATTR-CM, House China Committee July 17 Response Deadline Approaches for Lilly, Merck, AbbVie, Pfizer, BMS on Xinjiang and Military-Hospital Trial Sites

MindRank $52M Series B for oral GLP-1 MDR-001; White House FDA commissioner review; WaPo peptide showdown; AZ/Ionis Wainua Phase 3 miss; China trial letters.

5 stories · Covering industry, regulatory, clinical-trials

Editor's Note

Friday's digest reads as a running-story maintenance day. Chinese AI biotech MindRank closed a $52 million Series B to push MDR-001, an AI-designed oral small-molecule GLP-1 receptor agonist, through the Phase 3 MOBILE trial (~750 participants) in China, extending the oral-GLP-1 competitive set beyond Foundayo and the Wegovy pill. In Washington, three FDA commissioner finalists surfaced through STAT News reporting on the White House review: policy adviser Heidi Overton, oncologist-executive Jeffrey Vacirca, and Department of Defense health official Stephen Ferrara. The Washington Post Health Brief followed with a July 9 'peptide showdown' column from Megan Wilson, sustaining the mainstream-media coverage wave that NPR opened Wednesday. On the biologic-adjacent nucleic-acid side, AstraZeneca and Ionis' Wainua (eplontersen) missed its Phase 3 CARDIO-TTRansform primary composite endpoint in ATTR-CM, though nominal monotherapy signal held; ESC Congress in August 2026 is the venue for full results. And with the House China Select Committee's July 17 response deadline one week away, five drugmakers including Eli Lilly (11 Xinjiang-region trials, 16 military-medical-center trials) are compiling due-diligence and data-protection records on their China trial sites.

Industry

Chinese AI Biotech MindRank Announces $52 Million Series B Financing on Thursday July 9 to Advance MDR-001, an AI-Designed Oral Small-Molecule GLP-1 Receptor Agonist Now in Phase 3 MOBILE Trial in China (~750 Participants, 52-Week Efficacy and Safety in Adults with Overweight or Obesity), Cumulative R&D Investment From Project Initiation to Phase 3 Approximately $23 Million

MindRank AI, a Chinese clinical-stage biotech built around a proprietary Molecule Arts Platform (MAP) integrating biology, chemistry, computation, experimental evidence, and clinical learning, announced Thursday July 9, 2026 the completion of a $52 million Series B financing led by a group of institutional and healthcare funds. The company's lead program, MDR-001, is an AI-designed oral small-molecule GLP-1 receptor agonist that entered Phase 3 development in China in 2025 with the initiation of the MOBILE Phase 3 trial enrolling approximately 750 participants with overweight or obesity. The trial evaluates 52-week efficacy and safety. MindRank reports cumulative R&D investment from project initiation through the start of Phase 3 in China of approximately $23 million, with the program advancing from concept to Phase 3 in roughly 4.5 years. The financing extends the oral-GLP-1 competitive set beyond Eli Lilly's Foundayo (orforglipron), Novo Nordisk's Wegovy pill (oral semaglutide 25 mg), and Structure Therapeutics' aleniglipron. Anticipated commercial launch: within two to three years.

#mindrank #mdr-001 #oral-glp-1 #ai-drug-discovery #series-b #china #mobile-trial #phase-3 #obesity
Regulatory

White House Reviewing Three Finalists to Lead the FDA (STAT News Reporting, July 8-9): Heidi Overton (Current White House Policy Adviser), Jeffrey Vacirca (Oncologist and Health-System Executive), and Stephen Ferrara (Department of Defense Health Official) Emerged as the Shortlist Following the March 2026 Departure of Prior Commissioner; Peptide Policy Trajectory Runs Through Whichever Nominee Advances Given PCAC July 23-24 Vote and Ongoing Compounding-Rule Environment

STAT News' Pharmalot newsletter reported Wednesday-Thursday July 8-9, 2026 that the White House is reviewing three finalists to lead the FDA following the departure of the prior commissioner earlier in 2026: Heidi Overton, a policy adviser in the White House itself; Jeffrey Vacirca, an oncologist and health-system executive; and Stephen Ferrara, a health official at the Department of Defense. Axios first surfaced the shortlist on June 26; the July 8-9 STAT reporting confirmed the trio is under active White House review with a decision expected in the coming weeks. The peptide policy trajectory tracks through whichever nominee advances. FDA career-staff briefing documents released June 29-30 concluded all seven PCAC peptides have insufficient evidence for 503A eligibility, while HHS Secretary RFK Jr.'s public push points the other direction; the incoming commissioner will inherit an agency-vs-secretary tension around peptide compounding as the July 23-24 PCAC vote lands. The nominee will also inherit the pending Novo Nordisk-Vivani semaglutide-implant evaluation agreement, the Sandoz generic-tirzepatide ANDA acceptance from June 29, and the ongoing 503B GLP-1 exclusion rulemaking.

#fda #commissioner #white-house #heidi-overton #jeffrey-vacirca #stephen-ferrara #stat-news #pcac #peptide-policy
Industry

Washington Post Health Brief on Thursday July 9: 'The Peptide Showdown' — Reporter Megan R. Wilson Sustains the Mainstream-Media Coverage Wave With a Second WaPo Beat in Ten Days on the FDA Career-Staff Versus RFK Jr. Tension Two Weeks Before the July 23-24 PCAC Vote, Extending the Newspaper's June 30 'Peptides Are Popular and Controversial. Why?' Explainer Framework

The Washington Post Health Brief published Thursday July 9, 2026 a column by reporter Megan R. Wilson titled 'The peptide showdown,' sustaining WaPo's coverage of the FDA compounding-peptide review through a second full policy-newsletter beat in 10 days. The column extends the framework established in WaPo's June 30 general-audience explainer 'Peptides Are Popular and Controversial. Why?' The July 9 piece keeps the newspaper's mainstream-media pressure focused on the tension between FDA career scientists (June 29-30 briefing documents concluding all seven peptides have insufficient evidence for 503A eligibility) and HHS Secretary RFK Jr.'s public push to expand peptide compounding access. Combined with NPR's July 8 nationally syndicated feature ('What's behind the push to make peptide therapies more readily available'), the two consecutive mainstream-outlet beats push the panel-composition and evidence-base story past trade press (Endpoints, STAT, FiercePharma) and into general-audience awareness heading into the July 23-24 vote at White Oak.

#washington-post #megan-wilson #pcac #rfk-jr #peptide-showdown #mainstream-media #fda-briefing-documents #compounding
Clinical Trials

AstraZeneca and Ionis Announce Thursday July 9 That the Phase 3 CARDIO-TTRansform Trial of Wainua (Eplontersen, Antisense Oligonucleotide Nucleic-Acid Therapeutic) in Adults with Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) Missed Its Primary Composite Efficacy Endpoint of Cardiovascular Mortality and Recurrent Cardiovascular Events Through 140 Weeks Compared With Placebo; Prespecified Monotherapy Subgroup Analysis Showed Nominally Significant Composite-Event Reduction; Full Results to Be Presented at ESC Congress in August 2026

AstraZeneca and Ionis Pharmaceuticals announced Thursday July 9, 2026 that the Phase 3 CARDIO-TTRansform trial of Wainua (eplontersen) did not meet its primary efficacy endpoint in adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The trial enrolled over 1,400 patients and was the largest Phase 3 study conducted in the ATTR-CM population to date; the primary endpoint was a composite of cardiovascular mortality and recurrent CV clinical events through 140 weeks compared with placebo. Prespecified subgroup analyses showed nominally significant reductions in composite events with eplontersen monotherapy versus placebo, while patients also receiving a baseline TTR stabilizer showed no incremental effect. Eplontersen is an antisense oligonucleotide (a nucleic-acid therapeutic modality distinct from peptides but adjacent in the metabolic-and-cardiovascular therapeutic territory this site tracks); the drug is already FDA-approved as Wainua for hereditary transthyretin amyloidosis polyneuropathy. Full CARDIO-TTRansform results will be presented at the European Society of Cardiology (ESC) Congress in August 2026. AstraZeneca and Ionis shares fell on the readout.

#astrazeneca #ionis #wainua #eplontersen #cardio-ttransform #attr-cm #antisense-oligonucleotide #phase-3-miss #esc-congress
Regulatory

House Select Committee on the Chinese Communist Party July 17 Response Deadline Approaches One Week Out for Eli Lilly, Merck, AbbVie, Pfizer, and Bristol-Myers Squibb on Chinese Clinical Trial Sites (June 29 Letters from Chair Rep. John Moolenaar); Lilly Disclosed Sponsoring at Least 11 Trials in Xinjiang-Region Hospitals Plus at Least 16 Trials at Chinese Military Medical Centers Across Type 2 Diabetes, Heart Disease, Obesity, Alzheimer's, Axial Spondyloarthritis, Breast Cancer, Lupus, Alopecia, Crohn's Disease, and Additional Indications

The House Select Committee on the Chinese Communist Party (chaired by Rep. John Moolenaar, R-Michigan) faces its July 17 response deadline one week from tomorrow for five drugmakers under national-security investigation over clinical trials conducted at Chinese sites: Eli Lilly, Merck, AbbVie, Pfizer, and Bristol-Myers Squibb. The letters, first reported by Reuters, were dated June 29 and asked companies to provide details of due diligence, data protection processes, and other standards at their trial sites in China, with particular attention to the Xinjiang region and military hospitals. Eli Lilly disclosed sponsoring at least 11 trials at Xinjiang-region hospitals plus at least 16 trials at Chinese military medical centers and hospitals, across type 2 diabetes, heart disease, obesity, Alzheimer's disease, axial spondyloarthritis, breast cancer, lupus, alopecia, Crohn's disease, and additional indications. The committee said it has no evidence of company wrongdoing but cites potential ethical and national-security risks. The letters run parallel to the BIOSECURE Act framework, the June 30 STAT Pharmalittle preview of the probe, and industry warnings from Fierce Biotech that the scrutiny risks 'huge distraction and expense' for US biopharma.

#house-china-committee #john-moolenaar #eli-lilly #merck #abbvie #pfizer #bristol-myers-squibb #xinjiang #clinical-trials #national-security #biosecure-act